RE:Is everyone gone?Nothing much to comment on besides the fact that their much increased financial position (and access, if needed, to an even bigger amount via a line of credit) gives them the negotiation upperhand when negotiating with partners in business development (licensing) deals. When minnows are swimming with whales (big pharma) they can and do see how desperate you are to do a deal (much thanks Mark Day ... not!). That desperation just went away ... heck, we could even take 001 to the clinic now if we so choose.
So, now we await the release of the 3 study results and show our partners and the biotech world more of the tremendous capabilities of xB3.